Greg is a partner at the firm and a leader in the firm’s Biotechnology patent group. He prepares and prosecutes U.S., foreign, and international patent applications. Greg also advises clients about patentability, inventorship, freedom-to-operate, and strategic product development.
Greg’s expertise covers many areas of biotechnology, including virology, immunology, oncology, neurobiology, and biochemistry. He has particular expertise in the patenting of engineered vaccines and antibodies, including live-attenuated, subunit, and mRNA vaccines, monoclonal antibodies, bispecific antibodies, antibody conjugates, and CAR T cells.
Greg has prepared and prosecuted patents for multiple technologies shown in Science Magazine’s annual “breakthrough of the year” list and manages several global patent portfolios that cover FDA-licensed large molecule therapeutics.
Greg joined Klarquist in 2007 as a summer associate and student law clerk. He became partner in 2018.